Home > YAP & > Verteporfin

Verteporfin

维替泊芬,CL-318952

Verteporfin 是苯并卟啉衍生物,是一种光敏剂,用于光动力学疗法。

目录号
EY0712
EY0712
EY0712
EY0712
纯度
99.55%
99.55%
99.55%
99.55%
规格
2 mg
5 mg
10 mg
50 mg
原价
430
860
1300
4500
售价
430
860
1300
4500
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Verteporfin was also found to inhibit autophagosome formation that does not require exposure to light. Verteporfin could target and modify p62 directly, a protein of scaffold and adaptor that binds both polyubiquitinated proteins destined for degradation and LC3 on autophagosomal membranes. Co-immunoprecipitation experiments demonstrated that crosslinked p62 oligomers retain their ability to bind to LC3 but show defective binding to polyubiquitinated proteins. Interestingly, small amounts of crosslinked p62 oligomers were detected in cells which were untreated, and other groups which were noted the accumulation of p62 forms with reduced SDS-PAGE mobility in cellular and animal models of oxidative stress and aging.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Schmidt-Erfurth U, et al. Surv Ophthalmol, 2000, 45(3), 195-214.
    [2] Brodowska et al (2014) The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp.Eye Res. 124 67.
    [3] Song et al (2014) Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. Cancer Res. 74 4170.
    [4] Liu-Chittenden et al (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev. 26 1300.

    分子式
    C41H42N4O8
    分子量
    718.79
    CAS号
    129497-78-5
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    >50 mg/mL
    Water
    <1 mg/mL
    Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00674323 Polypoidal Choroidal Vasculopathy Drug: Verteporfin Photodynamic Therapy|Drug: Ranibizumab Novartis Phase 4 2008-04-01 2011-04-15
    NCT00433017 Macular Degeneration|Choroidal Neovascularization Drug: Verteporfin Photodynamic Therapy|Drug: Ranibizumab|Drug: Placebo Novartis Phase 2|Phase 3 2007-05-01 2011-04-18
    NCT00436553 Macular Degeneration|Choroidal Neovascularization Drug: Verteporfin Photodynamic Therapy|Drug: Ranibizumab|Drug: Verteporfin Placebo|Drug: Ranibizumab Placebo Novartis Phase 3 2007-02-01 2011-03-23
    NCT00359164 Macular Degeneration Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab University of British Columbia Phase 2 2006-07-01 2008-08-12
    NCT03067051 Recurrent Prostate Cancer Drug: Verteporfin|Device: SpectraCure P18 System SpectraCure AB Phase 1 2017-03-13 2017-02-23
    NCT00473642 Age-Related Maculopathy|Choroidal Neovascularization Drug: Ranibizumab|Drug: Verteporfin|Drug: Verteporfin Oklahoma State University Center for Health Sciences|Novartis Phase 4 2007-05-01 2012-10-09
    NCT00574093 Neovascular Age Related Macular Degeneration Drug: Ranibizumab; Verteporfin Fondazione G.B. Bietti, IRCCS Phase 2 2008-01-01 2009-10-29
    NCT00242580 Macular Degeneration|Choroidal Neovascularization Drug: Verteporfin photodynamic therapy|Drug: Pegaptanib|Drug: Triamcinolone acetonide Novartis Pharmaceuticals|QLT Inc.|Novartis Phase 3 2005-09-01 2016-03-03
    NCT00729846 Age Related Macular Degeneration|Choroidal Neovascularization|Macular Edema Drug: Bevacizumab|Device: verteporfin photodynamic therapy reduced fluence|Device: verteporfin photodynamic therapy standardfluence California Retina Consultants|Novartis Phase 2 2006-05-01 2016-03-21
    NCT00049959 Basal Cell Carcinoma|Nevoid Basal Cell Carcinoma Syndrome|Gorlin Syndrome Drug: verteporfin PDT QLT Inc.|Novartis Phase 3 null 2011-03-01
    NCT01846273 Age-related Macular Degeneration; Polypoidal Choroidal Vasculopathy (PCV) Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham PDT Novartis Pharmaceuticals|Novartis Phase 4 2013-08-07 2017-02-13
    NCT02872064 Breast Neoplasms Drug: Verteporfin University College, London 2013-01-01 2017-03-16
    NCT00403442 Macular Degeneration Device: Verteporfin Therapy/ Drug: Bevacizumab Vitreous -Retina- Macula Consultants of New York|QLT Inc. Phase 1 2006-09-01 2008-07-29
    NCT03033225 Pancreatic Cancer Non-Resectable Drug: Verteporfin PDT Mayo Clinic Phase 2 2017-01-01 2017-01-24
    NCT01974622 Retinal Vascular Disorders Drug: Visudyne Manhattan Eye, Ear & Throat Hospital 2013-04-01 2013-10-28
    NCT01922102 Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Drug: Ranibizumab 0.5mg|Drug: Rranibizumab 0.5 mg|Drug: Verteporfin PDT Novartis Pharmaceuticals|Novartis Phase 3 2013-09-01 2017-02-19
    NCT00967213 Neovascular Age-related Macular Degeneration Drug: ranibizumab Novartis Korea Ltd.|Novartis Phase 3 2006-08-01 2016-04-21
    NCT00426998 Choroidal Neovascularization|Macular Degeneration Drug: Verteporfin|Drug: Bevacizumab Retinal Consultants Medical Group Phase 2 2006-04-01 2007-01-25
    NCT01019668 Central Serous Chorioretinopathy Drug: Verteporfin PDT, half-dose|Drug: verteporfin PDT, half-fluence Shin Kong Wu Ho-Su Memorial Hospital 2008-11-01 2011-07-22
    NCT00429962 Choroidal Neovascularization|Age-Related Macular Degeneration Drug: intravitreal ranibizumab|Drug: intravitreal ranibizumab & photodynamic therapy University Hospital, Basel, Switzerland Phase 3 2006-07-01 2009-04-06
    NCT01968486 Myopia, Degenerative Drug: PDT standard fluence, ranibizumab|Drug: PDT reduced fluence, ranibizumab|Drug: ranibizumab Second University of Naples Phase 1 2012-06-01 2013-10-25
    NCT00288561 Age-Related Macular Degeneration (ARMD) Drug: ranibizumab Novartis Phase 2 2004-11-01 2008-06-18
    NCT00134667 Age-Related Macular Degeneration Drug: Photodynamic Therapy (PDT) with Visudyne (verteporfin)|Drug: Macugen (pegaptanib sodium) Eyetech Pharmaceuticals|Pfizer Phase 4 2005-03-01 2007-01-12

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :